



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/083,198	05/22/1998	VENKATARAMAN BRINGI	021653.0138	3687

26118 7590 12/19/2001

BROBECK, PHLEGER & HARRISON, LLP
ATTN: INTELLECTUAL PROPERTY DEPARTMENT
1333 H STREET, N.W. SUITE 800
WASHINGTON, DC 20005

EXAMINER

MARX, IRENE

ART UNIT

PAPER NUMBER

1651

DATE MAILED: 12/19/2001

23

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 09/083,198	Applicant(s), Bringi
Examiner Irene Marx	Art Unit 1651



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on Oct 4, 2001

2a) This action is FINAL. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-3, 6-21, and 24-72 is/are pending in the application.

4a) Of the above, claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) 1-3, 6, 8-14, 16-21, 24-26, 28-31, 33-37, 39-49, 51-67, 70, and 71 is/are allowed.

6) Claim(s) 7, 15, 27, 32, 38, 50, 68, 69, and 72 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claims _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are objected to by the Examiner.

11) The proposed drawing correction filed on _____ is: a) approved b) disapproved.

12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

a) All b) Some* c) None of:

1. Certified copies of the priority documents have been received.

2. Certified copies of the priority documents have been received in Application No. _____.

3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

*See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

15) Notice of References Cited (PTO-892) 18) Interview Summary (PTO-413) Paper No(s). _____

16) Notice of Draftsperson's Patent Drawing Review (PTO-948) 19) Notice of Informal Patent Application (PTO-152)

17) Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____ 20) Other: _____

The amendment filed 10/4/01 is acknowledged. Claims 1-3, 6-21, and 24-72 are being considered on the merits.

To clarify the invention and for the sake of consistency, "a" should be added before saccharide in claim 66.

The Bringi Declaration is persuasive regarding the amendment of the specification to replace 3-Iodophenoxyacetic acid with 4-Iodophenoxyacetic.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 7, 32, 38, 50, 68, 69, 72 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 7 is confusing in that it recites an improper Markush grouping because "and" is missing. Conjunctive language should be used (e.g. selected from the group consisting of A,B, AND C). The claims as drafted do not follow this form. See MPEP 2173.05(h)(a).

As noted previously, to clarify the invention, in claim 15, "ACC" should be spelled out.

Claim 32 is confusing at least in the recitation of "Mastoparan", "Mecoprop", "Chlorflurenol" and "Chlorpropham". The nature of these materials is not readily apparent, even when reading the claim in light of the specification.

Claim 50 is confusing in the recitation of "said the medium" at line 1.

Claim 68 is vague and indefinite in the recitation of "a compound selected from the group consisting of polyamines", particularly since claim 69 is directed to "said polyamines". Is one compound or several compounds intended? Claim 69 fails to find proper antecedent basis in claim 68 for "said polyamines", since claim appears to be directed to one compound.

Claim 72 is confusing in that it is unclear what is deemed to be "an amount sufficient to enhance taxane production" regarding the addition of β -phenylalanine, even when interpreting the claim in light of the specification. The amount of enhancement of taxane production is also

unclear. As noted previously, at page 25 of the specification this compound is disclosed as a biosynthetic precursor of taxane production. However, a disclosure regarding the amount required for this purpose is not clearly found at the indicated page of the specification.

As noted in the last Office action, Table 2 should be replaced. The last line thereof is illegible. A corrected table is not of record..

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Irene Marx whose telephone number is (703) 308-2922. The examiner can normally be reached on Monday through Friday from 6:30 AM to 3:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Wityshyn, can be reached on (703) 308-4743. The appropriate fax phone number for the organization where this application or proceeding is assigned is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to Customer Service whose telephone number is (703) 308-0198 or the receptionist whose telephone number is (703) 308-1235.

Irene Marx
Irene Marx
Primary Examiner
Art Unit 1651